Yutaka Kawakami

21.9k total citations · 4 hit papers
263 papers, 15.1k citations indexed

About

Yutaka Kawakami is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Yutaka Kawakami has authored 263 papers receiving a total of 15.1k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Immunology, 93 papers in Molecular Biology and 89 papers in Oncology. Recurrent topics in Yutaka Kawakami's work include Immunotherapy and Immune Responses (114 papers), Immune Cell Function and Interaction (49 papers) and T-cell and B-cell Immunology (49 papers). Yutaka Kawakami is often cited by papers focused on Immunotherapy and Immune Responses (114 papers), Immune Cell Function and Interaction (49 papers) and T-cell and B-cell Immunology (49 papers). Yutaka Kawakami collaborates with scholars based in Japan, United States and France. Yutaka Kawakami's co-authors include Steven A. Rosenberg, Paul F. Robbins, Ettore Appella, Hidetoshi Sumimoto, Masataka Kuwana, S Eliyahu, Yasuo Ikeda, Suzanne L. Topalian, Licia Rivoltini and C H Delgado and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Yutaka Kawakami

258 papers receiving 14.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

1994 886 citations Yutaka Kawakami et al. profile →
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

1994 742 citations Yutaka Kawakami, Gosse J. Adema et al. profile →
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

2006 528 citations Yutaka Kawakami et al. The Journal of Experimental Medicine profile →
Identification of human cancers deficient in antigen processing.

1993 522 citations Yutaka Kawakami et al. The Journal of Experimental Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yutaka Kawakami Japan	62	9.0k	6.0k	5.5k	1.3k	1.2k	263	15.1k
Nagahiro Minato Japan	59	10.2k 1.1×	4.3k 0.7×	8.5k 1.6×	944 0.7×	933 0.8×	212	18.4k
Hitoshi Kikutani Japan	65	9.2k 1.0×	4.4k 0.7×	3.9k 0.7×	1.4k 1.1×	1.7k 1.4×	186	17.0k
Vassiliki A. Boussiotis United States	61	9.5k 1.1×	3.8k 0.6×	5.5k 1.0×	575 0.4×	744 0.6×	182	15.6k
David J. Rawlings United States	67	9.5k 1.1×	5.2k 0.9×	2.4k 0.4×	1.1k 0.8×	2.6k 2.2×	260	16.3k
David M. Tarlinton Australia	68	12.3k 1.4×	4.8k 0.8×	2.5k 0.5×	1.5k 1.2×	842 0.7×	183	17.0k
Koji Tamada Japan	54	11.8k 1.3×	2.8k 0.5×	10.6k 1.9×	683 0.5×	922 0.8×	147	17.4k
Martin Turner United Kingdom	67	8.6k 1.0×	7.8k 1.3×	2.7k 0.5×	1.3k 1.0×	1.0k 0.9×	208	17.6k
André Veillette Canada	67	9.9k 1.1×	5.7k 0.9×	3.5k 0.6×	1.8k 1.4×	803 0.7×	182	14.7k
Michele W.L. Teng Australia	56	8.3k 0.9×	3.6k 0.6×	9.2k 1.7×	588 0.5×	716 0.6×	95	15.0k
Patrick Hwu United States	59	10.0k 1.1×	4.4k 0.7×	9.4k 1.7×	581 0.5×	1.6k 1.3×	220	15.8k

Countries citing papers authored by Yutaka Kawakami

Since Specialization

Citations

This map shows the geographic impact of Yutaka Kawakami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yutaka Kawakami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yutaka Kawakami more than expected).

Fields of papers citing papers by Yutaka Kawakami

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yutaka Kawakami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yutaka Kawakami. The network helps show where Yutaka Kawakami may publish in the future.

Co-authorship network of co-authors of Yutaka Kawakami

This figure shows the co-authorship network connecting the top 25 collaborators of Yutaka Kawakami. A scholar is included among the top collaborators of Yutaka Kawakami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yutaka Kawakami. Yutaka Kawakami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fukuda, Keitaro, Ken Okamura, Rebecca L. Riding, et al.. (2021). AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. The Journal of Experimental Medicine. 218(9). 57 indexed citations

Sugihara, Eiji, Satoru Osuka, Takatsune Shimizu, et al.. (2020). The Inhibitor of Apoptosis Protein Livin Confers Resistance to Fas-Mediated Immune Cytotoxicity in Refractory Lymphoma. Cancer Research. 80(20). 4439–4450. 10 indexed citations

Nakajima, Takako Eguchi, Shigenori Kadowaki, Keiko Minashi, et al.. (2020). Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer. Clinical Cancer Research. 27(4). 1029–1036. 63 indexed citations

Tamura, Ryota, Masato Fujioka, Yukina Morimoto, et al.. (2019). A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nature Communications. 10(1). 5758–5758. 37 indexed citations

Fukaya, Raita, Shigeki Ohta, Tomonori Yaguchi, et al.. (2016). MIF Maintains the Tumorigenic Capacity of Brain Tumor–Initiating Cells by Directly Inhibiting p53. Cancer Research. 76(9). 2813–2823. 56 indexed citations

Ogawa, Yoko, Satoru Morikawa, Hideyuki Okano, et al.. (2016). MHC-compatible bone marrow stromal/stem cells trigger fibrosis by activating host T cells in a scleroderma mouse model. eLife. 5. e09394–e09394. 30 indexed citations

Namiki, Takeshi, Tomonori Yaguchi, Kenta Nakamura, et al.. (2015). NUAK2 Amplification Coupled with PTEN Deficiency Promotes Melanoma Development via CDK Activation. Cancer Research. 75(13). 2708–2715. 25 indexed citations

Tsujikawa, Takahiro, Tomonori Yaguchi, Naoshi Kawamura, et al.. (2014). Aberrant Myosin 1b Expression Promotes Cell Migration and Lymph Node Metastasis of HNSCC. Molecular Cancer Research. 13(4). 721–731. 44 indexed citations

Kudo‐Saito, Chie, et al.. (2014). Induction of Immunoregulatory CD271+ Cells by Metastatic Tumor Cells That Express Human Endogenous Retrovirus H. Cancer Research. 74(5). 1361–1370. 43 indexed citations

10.

Kudo‐Saito, Chie, et al.. (2013). Targeting FSTL1 Prevents Tumor Bone Metastasis and Consequent Immune Dysfunction. Cancer Research. 73(20). 6185–6193. 61 indexed citations

11.

Shimizu, Takatsune, T. Ishikawa, Arisa Ueki, et al.. (2012). Fibroblast Growth Factor-2 Is an Important Factor that Maintains Cellular Immaturity and Contributes to Aggressiveness of Osteosarcoma. Molecular Cancer Research. 10(3). 454–468. 30 indexed citations

12.

Baba, Toshiyuki, Akihiko Itoh, Naoki Oyaizu, et al.. (2010). Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402. Journal of Translational Medicine. 8(1). 84–84. 21 indexed citations

13.

Tsukamoto, Nobuo, et al.. (2009). Impairment of Plasmacytoid Dendritic Cells for IFN Production by the Ligand for Immunoglobulin-Like Transcript 7 Expressed on Human Cancer Cells. Clinical Cancer Research. 15(18). 5733–5743. 25 indexed citations

14.

Goto, Yasufumi, Yuriko Matsuzaki, Ayako Shimizu, et al.. (2006). A New Melanoma Antigen Fatty Acid–Binding Protein 7, Involved in Proliferation and Invasion, Is a Potential Target for Immunotherapy and Molecular Target Therapy. Cancer Research. 66(8). 4443–4449. 48 indexed citations

15.

Yokota, Takafumi, Yutaka Kawakami, Yoshinori Nagai, et al.. (2005). Bone Marrow Lacks a Transplantable Progenitor for Smooth Muscle Type α -Actin–Expressing Cells. Stem Cells. 24(1). 13–22. 54 indexed citations

16.

Ohnishi, Mutsuko, Toshiharu Sakurai, Yuji Heike, et al.. (2005). Evaluation of cytomegalovirus‐specific T‐cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon‐γ‐enzyme‐linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T‐cell epitope. British Journal of Haematology. 131(4). 472–479. 37 indexed citations

17.

Kodama, Hiroaki, Takafumi Inoue, Ryuichi Watanabe, et al.. (2005). Cardiomyogenic Potential of Mesenchymal Progenitors Derived from Human Circulating CD14 ⁺ Monocytes. Stem Cells and Development. 14(6). 676–686. 44 indexed citations

18.

Ohashi, Yohei, Masakazu Ueda, Takeshi Kawase, Yutaka Kawakami, & Masahiro Toda. (2004). Identification of an epigenetically silenced gene, RFX1, in human glioma cells using restriction landmark genomic scanning. Oncogene. 23(47). 7772–7779. 27 indexed citations

19.

Kawakami, Yutaka. (1999). Identification of human melanoma antigens recognized by tumor infiltrating T lymphocytes and their use for immunotherapy. 48. 179–189. 1 indexed citations

20.

Schreurs, Marco W.J., et al.. (1995). Identification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line. International Journal of Cancer. 62(1). 97–102. 105 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact